Reading IART? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IART free→Reading IART? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IART free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, IART is above typical. Peer multiples imply a price about 68% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because recent financials are weak or earnings quality is fragile. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $17.71. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $17 IART trades at 7× p/e, below its 23× p/e peer median. Our $54 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 68% below a flat-multiple fair value, below our forecast of about -1%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -0.14x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity.
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.53 → $0.48 (-8.6% / 30d). 1 raised, 5 cut, 9 covering analysts.
1 upgrade, 0 downgrades / 30d, 0 maintained. 20% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 31.7% avg surprise
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$198.
How much price usually moves either way.
On a bad day, this stock has moved -$481.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,479.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This will help assess if the company is recovering from previous declines.
Confirms:Organic revenue growth for Q1 2026 turns positive year over year.
Disproves:Organic revenue growth for Q1 2026 remains negative year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for IART yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Dr. Stuart Essig as President and Chief Executive Officer On May 5, 2026, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the “Start Date”). Dr. Essig succeeds Mojdeh Poul, who is departing fro…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
IART Integra Lifesciences Holdings | Above typical Show detailsSector percentile: 79 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company has reiterated its revenue guidance range for 2026 to be between $1.662 billion and $1.702 billion.
The company updated its 2026 adjusted EPS guidance to a range of $2.40 to $2.50 per share.
The company expects reported revenues for 2026-Q2 to be in the range of $410 million to $425 million.
Why it matters: Stable or growing revenue means success in changes made.
Confirms:Q1 2026 revenue growth stabilizes or improves above 1.3% year over year.
Disproves:Q1 2026 revenue growth declines below 1.3% year over year.
Why it matters: An EPS update will indicate how well the company is managing costs and profits.
Confirms:EPS guidance raised above $1.00 for 2026.
Disproves:EPS guidance lowered below $0.80 for 2026.
Why it matters: A clear plan from the new CEO could help calm investors after the change.
Confirms:A press release detailing a new strategic plan or vision for the company.
Disproves:No announcement or vague statements about future direction from the new CEO.
Why it matters: The new CEO's plan will change the company's path and affect investor trust.
Confirms one read:New plans were announced that match growth goals.
Confirms the other:There are no new plans or a delay in the strategy rollout.
Why it matters: New EPS guidance shows management's confidence in making things better.
Confirms:If adjusted EPS guidance goes above $2.50 per share, it shows strong performance.
Disproves:If adjusted EPS guidance drops below $2.40 per share, it shows ongoing problems.
Why it matters: Revenue growth shows how well the company is bouncing back.
Confirms one read:Revenue growth stays above 3% each year in the next reports.
Confirms the other:Revenue growth drops below 0% year over year.
Why it matters: This guidance will show if the company can sustain its growth trajectory.
Confirms one read:Management expects revenue growth to be over 10% for 2026.
Confirms the other:Management expects revenue growth to be under 5% for 2026.
Why it matters: This update will show if the company can meet its growth goals for 2026.
Confirms:Q2 revenue guidance raised above 5% growth year over year.
Disproves:Q2 revenue guidance lowered below 0% growth year over year.
of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Integra LifeSciences Holdings Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 7, 2026. At the Annual Meeting, the Company’s stockholders approved, among other things, Amendment No. 3 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “Plan…
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT As previously disclosed, on December 18, 2018, certain subsidiaries of Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), entered into a $150 million accounts receivable securitization facility (the “A/R Facility”) to reduce outstanding revolving borrowings under the Company’s senior credit facility and to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries. The d…
of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…